Poland· PL-100388900
Ilaris
A canakinumab product containing canakinumabum, registered in Poland by Novartis Europharm Limited. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Canakinumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC08 (canakinumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Canakinumab · ATC L04AC08
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Canakinumabum
- Manufacturer
- Novartis Europharm Limited
- Country
- Poland (PL)
- ATC code
- L04AC08
- ATC class
- Canakinumab
- Defined daily dose
- 2.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin07613421054038
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
374 interactions on record for canakinumab.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Canakinumab · interactions on record
374 records
- 30 severe
- 337 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- PrednisoneA07EA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Canakinumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandIlaris
- BelgiumIlaris 150 mg/mlNovartis Europharm
- CzechiaILARISNovartis Europharm Limited, Dublin
- SpainILARIS 150 MG/ML SOLUCION INYECTABLENovartis Europharm Limited
- NorwayIlarisNovartis Europharm Limited (1)
- SwedenIlaris 150 mg/ml Injektionsvätska, lösningNovartis Europharm Limited
- United KingdomIlaris 150mg powder for solution for injection vialsNovartis Pharmaceuticals UK Ltd
- IcelandIlarisNovartis Europharm Limited*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ilaris
- Liechtenstein · Ilaris
- Norway · Ilaris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ee9aa00a-89b4-4c17-8edd-40fabf8ea99f GET /v1/drugs/ee9aa00a-89b4-4c17-8edd-40fabf8ea99f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "150 mg/ml",
"packaging": "07613421054038 ¦ Rpz ¦ EU/1/09/564/004 ¦ 122998\n1 fiol. 150 mg /ml",
"substance": "Canakinumabum 150 mg/ml",
"common_name": "Canakinumabum",
"pl_product_id": "100388900",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about canakinumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.